Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209281 | 0.83 | TSHR (0.33) | TSHRMEN1CYP3A4KMT2A | |
| SCHEMBL10767800 | 0.80 | — | — | |
| SCHEMBL4751225 | 0.79 | MEN1 (0.50) | TSHRMEN1CYP3A4KMT2A | |
| SCHEMBL2122173 | 0.72 | — | — | |
| SCHEMBL2122168 | 0.72 | — | — | |
| SCHEMBL6325365 | 0.71 | MEN1 (0.34) | MEN1CYP3A4KMT2A | |
| SCHEMBL28709594 | 0.71 | MEN1 (0.57) | TSHRMEN1CYP3A4KMT2A | |
| SCHEMBL6325367 | 0.71 | MEN1 (0.34) | MEN1CYP3A4KMT2A | |
| SCHEMBL7550121 | 0.70 | — | — | |
| SCHEMBL7550116 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111683930-B | Novel isoxazole compound or salt thereof | 日本欧爱特农业科技株式会社 | 2023-06-27 | — | — | CN | disclosed |
| US-20230130617-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | RHODES TECHNOLOGIES (US) | 2023-04-27 | — | — | US | disclosed |
| CN-114096543-A | Application of nucleoside analogue or combination preparation containing nucleoside analogue in resisting virus | 中国科学院上海药物研究所 | 2022-02-25 | — | — | CN | disclosed |
| CN-110831923-A | Polymer compositions stabilized with organic polysulfides | 阿科玛股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10316042-B2 | Process for improved opioid synthesis | RHODES TECHNOLOGIES (US) | 2019-06-11 | — | — | US | disclosed |
| EP-2872516-B1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | RHODES TECH (US) | 2017-08-30 | — | — | EP | disclosed |
| CN-102137668-B | Pyrazolopyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX S.A. (CH) | 2016-05-18 | — | — | CN | disclosed |
| US-20150315203-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | RHODES TECHNOLOGIES | 2015-11-05 | — | — | US | disclosed |
| EP-2872516-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | Rhodes Technologies (US) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014013313-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | RHODES TECHNOLOGIES (US) | 2014-01-23 | — | — | WO | disclosed |
| EP-2348090-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2011-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315203-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | OPRK1, OPRM1, OPRD1 | TSHR 3155/4885MEN1 3876/4885CYP3A4 36/4885 |
| US-10316042-B2 | Process for improved opioid synthesis | OPRK1, OPRM1, OPRD1 | TSHR 3155/4885MEN1 3876/4885CYP3A4 36/4885 |
| US-20230130617-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | OPRK1, OPRM1, OPRD1 | TSHR 3276/4885MEN1 4481/4885CYP3A4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.